Search Results - "Crombé, Anne"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1

    Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1 by MCCORMICK, Adele L, PARRY, Chris M, CROMBE, Anne, GOODALL, Ruth L, GUPTA, Ravindra K, KALEEBU, Pontiano, KITYO, Cissy, CHIRARA, Michael, TOWERS, Greg J, PILLAY, Deenan

    Published in Antimicrobial Agents and Chemotherapy (01-04-2011)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

    Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results by Hess, Georg, Karola, Wagner, LaRosee, Paul, Keller, Ulrich, Atta, Johannes, Witzens-Harig, Mathias, Crombé, Anne, Medler, Christoph, Borchmann, Peter, Bitz, Ulrich, Lerchenmüller, Christian, Theobald, Matthias, Dreyling, Martin H.

    Published in Blood (02-12-2016)
    “…Background: mTOR inhibition has been shown to be effective in various subtypes of malignant lymphomas (Smith et al, JCO 2010). Furthermore, in relapsed MCL a…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial

    Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Results of the Part I Cohort of the STORM Trial by Witzens-Harig, Mathias, Keller, Ulrich, Viardot, Andreas, Buske, Christian, Crombé, Anne, Hoenig, Elisabeth, Meissner, Julia, Ho, Anthony D, Marks, Reinhard, Dreyling, Martin H., Hess, Georg

    Published in Blood (03-12-2015)
    “…Purpose. To evaluate the safety, tolerability and efficacy of the combination of the mTOR inhibitor Temsirolimus and a standard salvage regimen (R-DHAP) in…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial

    Safety and Clinical Activity of Temsirolimus in Combination with Rituximab and DHAP in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Report of the Prospective, Multicenter Phase II STORM Trial by Witzens-Harig, Mathias, Viardot, Andreas, Keller, Ulrich, Buske, Christian, Crombé, Anne, Hoenig, Elisabeth, Atta, Johannes, Schmier, Johann, Meissner, Julia, Ho, Anthony D., LaRosee, Paul, Marks, Reinhard, Dreyling, Martin, Hess, Georg

    Published in Blood (02-12-2016)
    “…Purpose. To evaluate the safety, tolerability and efficacy of the combination of the mTOR inhibitor Temsirolimus and a standard salvage regimen (R-DHAP) in…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: